Abstract
Despite the superior side effect profile of the newer antidepressants over the tricyclics and monoamine oxidase inhibitors, all newer antidepressants are associated with a wide array of side effects. Clinicians are constantly confronted with the challenge of managing these side effects in the context of minimal research to prove one management strategy is more effective than another. The purpose of this study was to examine prescribing practices regarding the management of SSRI-associated side effects in a sample of psychiatrists attending a psychopharmacology review course. A total of 439 out of 800 clinicians (55%) attending a psychopharmacology review course responded to our questionnaire that was given prior to beginning the review course, though not all respondents answered all four items on the questionnaire. Among these items were questions designed to assess clinician preference for the management of SSRI-induced side effects. As a treatment for SSRI-induced sexual dysfunction, 43% (143/330) chose adding bupropion, while 36% (120/330) opted to switch agents as their first choice; for SSRI-induced insomnia, 78% (264/326) chose adding trazodone. Switching agents was the first choice of 61% (214/353) of clinicians for managing SSRI-induced agitation, 93% (339/363) for managing SSRI-associated weight gain. In an effort to manage most SSRI-associated side effects (with the exception of sexual dysfunction and insomnia), the majority of the clinicians responding to our survey opted to switch agents rather than add a specific medication to the existing SSRI. In our opinion, this practice may reflect the relative lack of research studies on the role of adjunctive treatments in the management of SSRI-induced side effects and/or the tendency to favor monotherapy over polypharmacy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Fava M, Rosenbaum JF: Pharmacotherapy and somatic thera-pies. In: Beckham EE, Leber WR, eds. Handbook of Depres-sion. New York: Guilford Press; 1995:280-301
Montejo-Gonzalez AL, Llorca G, Azquierdo JA, Ledesma A, Bousono M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, Dela Gandara J, Derecho J, Frano M, Gomez MJ, Macias JA, Martin T, Perez V, Sanchez JM, Sanchez S, Vicens E: SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline, and flu-voxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997; 23(3):176-194
Gelenberg et al.: Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 2000; 61(50):356-360
Reich J: The sexual side effects of an SSRI treated by behav-ioral methods. J Nerv Ment Dis 1997; 185(11):707
Rothschild AJ: Selective serotonin reuptake inhibitor-induced sexual dysfunction: Efficacy of a drug holiday. AmJ Psychiatry 1995; 152(10):1514-1516
Fava et al.: An open trial of oral sildenafil in antidepressant-induced sexual dysfunction. Psychother Psychosom 1998; 67(6):328-331
Balon R: Intermittent amantadine for fluoxetine-induced anorgasmia. J Sex Marital Ther 1996; 22(4):290-292
Reynolds RD: Sertraline-induced anorgasmia treated with in-termittent nefazodone (letter). J Clin Psychiatry 1997; 58:89
Labbate LA, et al.: Bupropion treatment of serotonin reup-take antidepressant-associated sexual dysfunction. Ann Clin Psychiatry 1997; 9(4):241-245
Clayton AH, McGarvey EL, Abouesh AI, Pinkerton RC: Sub-stitution of an SSRI with bupropion sustained release follow-ing SSRI-induced sexual dysfunction. J Clin Psychiatry 2001; 62(3):185-190
Cohen AJ, Bartlik B: Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 1988; 24(2):139-143
Aizenberg E, et al.:Cyproheptadine treatment of sexual dys-function induced by serotonin reuptake inhibitors. Clin Neu-ropharmacol 1995; 18(4):320-324
Hollander E, McCarley A: Yohimbine treatment of sexual side effects induced serotonin reuptake blockers. J Clin Psychiatry 1992; 53(4):119-122
Bartlik BD, et al.: Psychostimulants apparently reverse sex-ual dysfunction secondary to selective serotonin reuptake in-hibitors. J Sex Marital Ther 1995; 21(4):264-271
Nurnenberg HG, Gelenberg A, Hargreave TB, Harrison WM, Siegel RL, Smith MD: Efficacy of sildenafil citrate for the reatment of erectile dysfunction in men taking serotonin re-uptake inhibitors. Am J Psychiatry 2001; 158(11):1926-1928
Michelson D, Amersterdam JD, et al.: Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999; 156(80):1170-1176
Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC: Fluoxetine versus Sertaline and Paroxetine in Major Depression: Long-Term Changes in Weight. In press
Nierenberg AA, et al.: Trazodone for antidepressant-associated insomnia. Am J Psychiatry 1994; 151(7):1069-1072
Asnis GM, et al.: Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 1999; 60(10):668-676
Croft H, Houser TL, Jamerson BD, Leadbetter R, Bolden-Watson C, Donaghue R, Metz A: Effects on body weight of bupropion sustained-release in patients with major depres-sion treated for 52 weeks. Clin Therapeut 2002; 24(4):662-672
Nurenberg HG, Seidman SM, Fava M, Rosen R, Shabsigh R, Gelenberg AJ: Depression, antidepressant therapy and erec-tile dysfunction: Clinical trials of sildenafil in treated and un-treated patients with depression. J Urol In press; 60(Suppl 4A):202
Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M: Strategies for Management of Depression Refractory to SSRI Treatment: A Survey of Clinicians
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dording, C.M., Mischoulon, D., Petersen, T.J. et al. The Pharmacologic Management of SSRI-Induced Side Effects: A Survey of Psychiatrists. Ann Clin Psychiatry 14, 143–147 (2002). https://doi.org/10.1023/A:1021137118956
Issue Date:
DOI: https://doi.org/10.1023/A:1021137118956